Fast Company Honors Braeburn Pharmaceuticals as Innovative

PRINCETON, NJ – February 13, 2017 – Braeburn Pharmaceuticals was named today by Fast Company as a Top 10 Most Innovative Company in Biotech in conjunction with its annual ranking of the world’s 50 Most Innovative Companies for 2017. Previous honorees in the top 10 most innovative biotech companies include Bristol-Myers Squibb, Amgen, and 23andMe.

Braeburn’s mission is to develop and deliver individualized, long-acting medicines to patients that suffer from serious, stigmatized neuropsychiatric disorders such as opioid addiction, chronic pain, and schizophrenia. In May 2016, Braeburn’s Probuphine® received FDA approval and became the first buprenorphine implant for the long-term maintenance treatment of opioid addiction. This year Braeburn plans to file a new drug application (NDA) for a weekly and monthly injectable buprenorphine for the treatment of opioid dependence, and to progress a six-month risperidone implant for the treatment of schizophrenia.

“The team at Braeburn Pharmaceuticals is focused on bringing cutting-edge innovations to underserved patient populations,” said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. “We developed our pipeline strategically to include long-acting injectable and implantable formulations that ensure patients can receive the optimal dose of medication on a continuous, long-term basis. This past year our team accomplished so much, but considering the epidemic scale of opioid addiction in the U.S. alone, our mission remains critical; the potential benefit of our work has never been more apparent.”

Most Innovative Companies is one of Fast Company’s most significant and highly-anticipated editorial efforts of the year. To produce the 2017 list, Fast Company surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture.

“Each year, our reporting team scours the globe to identify organizations that have been both innovative and impactful in their industry, the business world, and the larger culture,” said Robert Safian, Editor, Fast Company. “At a time marked by political and economic uncertainty, your ability to rise to the top of your field is especially meaningful and inspiring. I’m excited to welcome you to a dynamic inspiring class of companies from around the world.”

Fast Company’s Most Innovative Companies issue (March 2017) is now available online at www.fastcompany.com/MIC as well as in app form via iTunes, and on newsstands beginning February 21.

About Fast Company

Fast Company is the world’s leading progressive business media brand, with a unique editorial focus on innovation in technology, ethical economics, leadership, and design. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, one of the U.S.’s leading media companies.

About Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn’s pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.

About Probuphine

Probuphine is the only six-month treatment for opioid dependence that delivers buprenorphine continuously using Titan Pharmaceuticals’ (NASDAQ: TTNP) ProNeura™ technology. Probuphine is placed under the skin of the upper arm during a short outpatient office procedure and is removed in a similar manner. Probuphine is available through a closed distribution system. Qualified healthcare providers can register for Probuphine training at www.probuphineREMS.com or by calling 1-866-397-8939. Probuphine is available in all 50 U.S. States; people interested in finding a provider in their area can visit www.probuphinerems.com/probuphine-locator.

Probuphine Indication and Important Safety Information

PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent).

PROBUPHINE should be used as part of a complete treatment program to include counseling and psychosocial support.

PROBUPHINE is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet or generic equivalent.

WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL

Risk Associated with Insertion and Removal

Insertion and removal of PROBUPHINE are associated with the risk of implant migration, protrusion, expulsion resulting from the procedure. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion.

Because of the risks associated with insertion and removal, PROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing PROBUPHINE implants. Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to perform insertions.

Please see additional Important Safety Information in the Package Insert that can be found at probuphine.com or by following this link.

About Braeburn Pharmaceuticals

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn’s pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.

Media Contacts:

Caleb Cluff
Coltrin & Associates
212-221-1616
caleb_cluff@coltrin.com

Sherry Feldberg
MSLGROUP
781-684-0770
braeburnpharma@publicisgroupe.net